Compare PLUR & PSTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PLUR | PSTV |
|---|---|---|
| Founded | 2001 | 1996 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.9M | 27.9M |
| IPO Year | 2001 | 2016 |
| Metric | PLUR | PSTV |
|---|---|---|
| Price | $3.35 | $0.16 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $12.00 | $7.67 |
| AVG Volume (30 Days) | 5.5K | ★ 4.0M |
| Earning Date | 05-12-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 10.78 | ★ 87.61 |
| EPS | N/A | ★ N/A |
| Revenue | $1,336,000.00 | ★ $5,213,000.00 |
| Revenue This Year | $97.38 | $21.93 |
| Revenue Next Year | $293.97 | $279.39 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 309.82 | N/A |
| 52 Week Low | $2.82 | $0.16 |
| 52 Week High | $7.13 | $1.22 |
| Indicator | PLUR | PSTV |
|---|---|---|
| Relative Strength Index (RSI) | 51.18 | 22.25 |
| Support Level | $3.06 | N/A |
| Resistance Level | $3.50 | $0.32 |
| Average True Range (ATR) | 0.15 | 0.02 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 69.39 | 18.89 |
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, commercializing and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).